Navigation Links
Peregrine Pharmaceuticals to Report First Quarter FY 2010 Financial Results
Date:8/27/2009

TUSTIN, Calif., Aug. 27 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that it will release its financial results for the first quarter of fiscal year 2010 on September 3, 2009 at 7:00 a.m. EDT and will host a conference call and webcast to discuss the results at 11:30 a.m. EDT on the same day.

Peregrine's senior management will discuss financial results for the first quarter ended July 31, 2009 and will review recent operating highlights. A question-and-answer session will follow management's discussion. All interested parties are encouraged to listen to the live conference call or the archived webcast.

The conference call and webcast will begin at 11:30 a.m. EDT/ 8:30 a.m. PDT. To listen to a live broadcast of the call over the Internet or to review the archived webcast, please visit: www.peregrineinc.com. The webcast will be archived on Peregrine's website for 30 days.

To listen to the conference call via telephone, please call the following number approximately 10 minutes prior to the scheduled start time and request to join the Peregrine Pharmaceuticals call: (800) 860-2442. A telephonic replay of the conference call will be available starting approximately one hour after the conclusion of the call through September 10, 2009 by calling (877) 344-7529, passcode 431883#.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and hepatitis C virus infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

    Contacts:
    GendeLLindheim BioCom Partners
    Investors                                       Media
    info@peregrineinc.com                           Barbara Lindheim
    (800) 987-8256                                  (212) 918-4650


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Peregrine Pharmaceuticals to Present at the Jesup & Lamont 2009 Growth Stock & National Sales Conference
2. Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech
3. Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine
4. Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
5. Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
6. Clinical Data on Peregrines Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting
7. Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial
8. Peregrine Pharmaceuticals Awarded New U.S. Patent Further Strengthening Its Anti-Phospholipid Patent Portfolio
9. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
10. Peregrine Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
11. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. ... the faculty of the University of North Carolina Kenan-Flagler Business School ... entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international efforts, leading ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, one of the ... brand, UP4™ Probiotics, into Target stores nationwide. The company, which has been manufacturing ... to its list of well-respected retailers. This list includes such fine stores as ...
(Date:6/23/2016)... HOUSTON , June 23, 2016 ... agreement with the Cy-Fair Sports Association to serve ... of the agreement, Houston Methodist Willowbrook will provide ... education and connectivity with association coaches, volunteers, athletes ... partner with the Cy-Fair Sports Association and to ...
Breaking Biology Technology:
(Date:5/9/2016)... , UAE, May 9, 2016 ... it comes to expanding freedom for high net worth ... Even in today,s globally connected world, there is still ... system could ever duplicate sealing your deal with a ... second passports by taking advantage of citizenship via investment ...
(Date:4/26/2016)... India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a product ... and Onegini today announced a partnership to integrate ... solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... to provide their customers enhanced security to access ...
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
Breaking Biology News(10 mins):